FDA Approves New Weight-Loss Product

Text Size:
FDA Approves New Weight-Loss Product

The U.S. Food and Drug Administration (FDA) has approved Plenity, a new prescription weight-loss product for people who are ineligible for gastric bypass surgery.

Intended for use as a weight-loss aid in those with a body-mass index (BMI) of 25-40 kg/m2, the product is “an oral superabsorbent biodegradable hydrogel that expands in the stomach to create pressure on the stomach walls and increase the feeling of satiety.” According to Time, the capsules can fill roughly a quarter of the stomach without contributing any calories. In a clinical trial, 59 percent of patients receiving the product achieved at least a 5 percent weight loss.

Pricing has not yet been set for Plenity, which is expected to launch in the second half of 2019 and become widely available in 2020.

Want to learn more about weight management? Read “Tried and True Weight-Loss Techniques,” “Strategies for Weight Management,” and “Why Can’t I Lose Weight?”


The latest delivered straight to your inbox

Learn More


Subscribe to Stay Informed

Sign up for Free

Get the latest diabetes news and a free gift!

Learn More

Save Your Favorites

Save This Article